Abstract
Chronic alcohol exposure can lead to alcoholic liver disease, including hepatitis, cirrhosis and hepatocellular carcinoma, and chronic inflammation can simultaneously cause systemic medical illness. Recent evidence suggests that alcoholic liver disease is a predictor for liver-related diseases, cardiovascular disease, immunologic disease, and bone disease. Chronic inflammation in alcoholic liver disease is mediated by a direct inflammatory cascade from the alcohol detoxification process and an indirect inflammatory cascade in response to gut microflora-derived lipopolysaccharides (LPS). The pathophysiology of alcoholic liver disease and its related systemic illness is characterized by oxidative stress, activation of the immune cascade, and gut-liver interactions. Integrative therapeutic strategies for alcoholic liver disease include abstaining from alcohol consumption; general anti-inflammatories such as glucocorticoid, pentoxifylline, and tumour necrosis factor-α antagonist; antioxidants such as N-acetylcysteine; gut microflora and LPS modulators such as rifaximin and/or probiotics. This review focuses on the impact of chronic liver inflammation on systemic health problems and several potential therapeutic targets.

Key words: Alcoholic liver disease; Oxidative stress; Cardiovascular disease; Immunologic disease; Bone disease

Core tip: Beyond the natural course in the liver, alcoholic liver disease can be implicated in many health problems that affect the quality of life and disease progression. Evidence suggests that alcoholic liver disease is a predictor for liver-related diseases, cardiovascular disease, immunologic disease, and bone disease. Chronic inflammation in alcoholic liver disease and related systemic illness is mediated by a direct response to alcohol and an indirect inflammatory response. Alcoholic liver disease should be considered from the perspective of chronic inflammation. Accordingly, integrative therapeutic strategies including anti-inflammatory targeting are needed for alcohol-induced liver inflammation management and prevention of systemic medical problems.

INTRODUCTION
Chronic alcohol consumption is a major risk factor for chronic liver disease worldwide. Cardinal features of alcoholic liver disease include simple fatty liver, alcoholic hepatitis, fibrosis or, more seriously, cirrhosis and hepato-
tocellular carcinoma. Alcohol has been recognized as a true hepatotoxin, an agent able to cause liver damage, for many years[1]. Although abstaining from alcohol is the primary recommendation for managing alcoholic liver disease, the chronic features of alcoholic liver disease and its progression can affect a patient’s attitude toward consumption. Alcohol is an important cause of hepatocellular carcinoma in Korea in addition to the hepatitis B virus and the hepatitis C virus[2]. Additionally, up to 48% of cirrhosis-related deaths have been associated with alcohol in the United States[3].

Recent evidence has determined that inflammation is closely linked with development of alcoholic liver disease[4-7]. Acute inflammation as a defense against noxious stimuli is very important for homeostasis in the body, whereas chronic exposure to an agent that induces inflammation may cause a dysregulated or unresolved inflammatory response, which causes chronic inflammation. Finally, various inflammatory components can influence systemic medical conditions. The major sources of chronic low-grade inflammation in alcoholic liver disease are categorized as follows: a direct inflammatory cascade from the alcohol detoxification process and an indirect inflammatory cascade in response to gut microflora-derived lipopolysaccharides (LPS).

The liver plays a key role in detoxifying alcohol and its related toxic products and is also responsible for immunologic effects. However, chronic alcohol consumption can lead to alcoholic liver disease and simultaneous systemic medical illness because of chronic inflammation. Beyond the natural course in the liver, alcoholic liver disease can be implicated in many health problems that affect the quality of life and disease progression. Therefore, alcoholic liver disease should be considered from the perspective of chronic inflammation. This review focuses on the impact of chronic liver inflammation on systemic health problems and several potential therapeutic targets.

**CARDIOVASCULAR DISEASE**

Emerging evidence suggests that alcoholic liver disease predicts not only liver-related diseases, but also atherosclerotic cardiovascular disease (CVD). Recent data suggest that some pathogenic mechanisms are involved in atherosclerotic CVD. In patients with alcoholic liver disease, alcohol, acetaldehyde, and excessive free fatty acids (FFA) in hepatocytes generate an excess of reactive oxygen species (ROS). This formation leads to lipid peroxidation, cytokine production, and hepatic inflammation[8], which contribute to a higher oxidative-inflammatory response. Thus, alcoholic liver disease may actively involve chronic low-grade inflammation in the arterial wall[9]. Moreover, pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-17 (IL-17) are produced by Kupffer cells in the liver in response to LPS, which, in turn, play a key role in inducing acute phase reactants in the liver, such as C-reactive protein (CRP), ferritin, and amyloid A[10,11]. These inflammatory cascades can also synergistically or interactively contribute to arterial inflammation. Indeed, several epidemiologic studies have shown that various inflammatory markers, such as TNF-α and CRP, are elevated in patients with alcoholic liver disease[12-14]. Furthermore, chronic low-grade inflammation plays a crucial role in regulating arterial wall tone by affecting the release of nitric oxide (NO) and endothelin-1[15,16]. These cascades may cause endothelial dysfunction and alter arterial elastic properties, leading to arterial stiffness. In addition, when a hepatic cell is damaged, hepatic stellate cells also secrete angiostatin II[17], a major pro-atherogenic and vasoconstrictive peptide that acts on the arterial wall. The overproduction of hemostatic factors such as plasminogen activator inhibitor-1 (PAI-1) may have a direct atherogenic effect on blood vessels in patients with alcoholic liver disease. Lastly, chronic alcohol consumption has a tendency for increased plasma homocysteine levels, albeit the results are inconsistent according to amount and types of alcoholic beverage consumed, or underlying diseases[18]. However, hyperhomocysteinemia induced by chronic alcohol consumption may be one of the important risk factors for CVD[19,20].

**IMMUNOLOGIC DISEASE**

Recent research has shown that alcoholic liver disease may alter immune regulation, which can lead to immunodeficiency and autoimmunity[21]. Additionally, individuals with chronic alcohol consumption are more susceptible to bacterial pneumonia and septicemia[22-24]. There is also an increased incidence of pulmonary tuberculosis or human immunodeficiency virus (HIV) in patients with alcoholic liver disease[26-28]. In addition, less common infectious diseases such as meningitis, diphtheria, lung abscess, or cellulitis are more prevalent in alcoholic liver disease[29].

Alcoholic hepatitis and alcoholic liver cirrhosis have been associated with autoimmune properties[30]. Liver function in patients with alcoholic hepatitis can decrease for several weeks (at least two weeks) after abstinence from alcohol, and resuming drinking after recovering from alcoholic hepatitis can lead to more severe alcoholic hepatitis. In this regard, autoantibodies against the liver may be an important cause of the liver damage and scarring in alcoholic liver disease.

Other autoimmune diseases or allergic reactions are also seen in alcoholic liver disease. Immunoglobulin A (IgA) has been found in skin and kidney deposits as well as the liver in many patients with alcoholic liver disease[31]. Also, alcohol consumption contributes to immunoglobulin E (IgE)-mediated reactions in susceptible humans, such as individuals with food allergies or asthma[32]. Chronic alcohol use has been found to increase total IgE level[33-35]. Therefore, understanding altered immunity and cytokines in alcoholic liver disease can be
important for assessing potential immunologic risk and could provide insight into therapeutic targets.

**BONE DISEASE**

Hepatic osteodystrophy is abnormal bone metabolism that has been identified in association with chronic liver disease, including such conditions as osteopenia, osteoporosis, and osteomalacia. The prevalence of osteopenia in patients with alcoholic liver disease is between 34% and 48%, and the prevalence of osteoporosis is between 11% and 36%.[33-35] However, osteomalacia has rarely been confirmed in patients with chronic liver disease and low vitamin D level[36,37].

Bone is a dynamic tissue that is remodeled through constant bone resorption and formation. Bone turnover accounts for up to 15% of the annual renovation of total bone mass.[38] Decreased bone density, commonly seen in hepatic osteodystrophy, results from decreased bone formation or increased bone resorption. Bone mineral density, measured by dual energy X-ray absorptiometry, is reported with a Z score and T score; the former is used to compare the patient’s bone mineral density with an age-matched mean value, and the latter is used to compare the bone mineral density with that of healthy young individuals. Osteopenia is identified when a T score ranges from -1.0 to -2.5, and osteoporosis is defined by a T score < -2.5. Osteomalacia is characterized by abnormal bone matrix mineralization, which can be confirmed by bone biopsy. These metabolic bone diseases are very common and can be important complications in patients with alcoholic liver disease. Although the mechanism of metabolic bone diseases remains complex and multifactorial, osteoclastogenic inflammatory cytokines, such as interleukin 1 (IL-1) and TNF-α, have been known to have a key role in the pathogenesis of bone metabolic disease that is related to alcoholic liver disease.[39] Early assessment and therapeutic intervention in patients with hepatic osteodystrophy can be important for minimizing future fracture risk and maintaining the quality of life.

**PATHOPHYSIOLOGY**

**Oxidative stress**

It is known that alcohol increases ROS, which are chemically reactive molecules that can damage various cellular components such as proteins, lipids, or deoxyribonucleic acid (DNA).[40] Moreover, acetaldehyde, an intermediate alcohol metabolite, is a highly reactive compound and is highly toxic to hepatocytes, promotes glutathione depletion, lipid peroxidation, and mitochondrial damage.[41-43] Evidence suggests that oxidative stress can contribute to the development of alcoholic liver disease and has been associated with various major diseases including cardiovascular diseases, type 2 diabetes, neurodegenerative disease, and carcinogenesis.[43-46]

Although multiple mechanisms are involved in alcohol-related ROS production, cytochrome P450 E21 and the mitochondrial electron transport chain are important targets.[40,47,48] Moreover, alcohol-derived ROS may directly trigger the systemic inflammatory response[49]. ROS could activate nuclear factor kappa B (NF-κB), which leads to production of inflammatory cytokines such as TNF-α. Alcohol-derived ROS may play a role in initiating a vicious cycle via the liver cell damage mechanism with additional inflammatory cytokines and ROS production.[50] Therefore, alcohol-derived ROS may be important for understanding systemic inflammation accompanied with alcoholic liver disease.

**Activation of immunity**

As described above, individuals with chronic alcohol consumption are more susceptible to immunodeficiency and autoimmunity. Understanding altered innate and acquired immunity in alcoholic liver disease may be important for assessing the potential risk of opportunistic infections and allergic diseases such as food allergies and bronchial asthma.

Alcohol consumption causes gut microflora dysbiosis and bacterial over-growth and ultimately increases gut permeability and the translocation of LPS from the gut to the liver. In Kupffer cells, gut microflora-derived-LPS interacts with toll-like receptor 4 (TLR4), and pro-inflammatory cytokines and chemokines such as TNF-α, IL-8, IL-17 are produced, leading to the production of ROS and alcohol-induced liver damage.[51,52] Interestingly, activation of TLR4 also induces Kupffer cells to produce hepatoprotective cytokines such as IL-6 which reduces hepatocyte necrosis-associated inflammation, albeit having proinflammatory roles, and anti-inflammatory cytokines such as interleukin-10 (IL-10).[53] However, long-term alcohol consumption may generate lipid peroxidation products such as malondialdehyde (MDA) as a result of ROS cascades, which can modify many proteins linked to the adaptive immune response.[54,55] Patients with alcoholic liver disease have increased levels of circulating antibodies against lipid peroxidation products and increased numbers of T and B cells in the liver, which contribute to adaptive immunity activation in alcoholic liver disease.[54,55].

**Gut-liver interaction**

Optimal functioning of the gut-liver axis depends on healthy gut integrity and mucosal microflora and a healthy liver; however, chronic alcohol exposure impairs both gut and liver health. These changes affect each other and ultimately contribute to the increased blood levels of LPS, or endotoxemia, in patients with alcoholic liver disease. Major inducers of chronic low-grade inflammation in alcoholic liver disease are broadly summarized as a direct inflammatory injury from alcohol and its metabolites or an indirect inflammatory injury in response to LPS. The microflora-derived LPS enters systemic circulation in two different ways, either via a portal vein or through gastrointestinal lymphatic vessels.[56,57] Most LPS
in the lymphatic system move through mesenteric lymph nodes and eventually enter the systemic circulation at the thoracic duct opening, whereas most LPS in the portal vein can be detoxified and excreted.

Alcohol can alter gut integrity and permeability in both direct and indirect manners. Alcohol and its metabolites such as acetaldehyde can directly alter both gut permeability and microflora content and composition. Alcohol and acetaldehyde can weaken the intestinal epithelial barrier, such as tight junctions between intestinal enterocytes. Moreover, increased gut permeability in alcoholic liver disease may be aggravated by increased expression of inducible nitric oxide synthase (iNOS) and NF-κB, which, in turn, enhance the translocation of LPS between tight junctions of adjacent enterocytes\(^ {[58,59]} \). This increased gut permeability is also called leaky gut syndrome (LGS). Patients with alcoholic hepatitis commonly show elevated LPS levels in plasma, implicating a crucial role of LPS-induced inflammation in the pathogenesis of alcoholic liver disease\(^ {[60]} \). Thus, alcohol facilitates the translocation of endotoxin from the intestinal lumen to the portal vein, thereby aggravating the risk of liver injury.

Individuals with chronic alcohol use are more susceptible to small intestinal bacterial overgrowth and dysbiosis compared to counterpart non-alcoholics or abstainers\(^ {[61,62]} \). Excessive alcohol ingestion facilitates the overgrowth of Gram-negative bacteria, contributing to increased endotoxin levels\(^ {[63]} \). In addition, micronutrient deficiency, such as zinc, is common in alcoholic liver disease, which adversely affects the integrity of the intestinal epithelium\(^ {[63]} \). More recently, evidence suggests that increased gut permeability may be an important factor in the pathogenesis of alcoholic liver disease.

As intestinal permeability increases, endotoxin and other bacterial toxins increase the sensitivity of Kupffer cells to LPS stimulation in the liver, where increased pro-inflammatory cytokines lead to neutrophil activation, increased sinusoidal permeability, generation of ROS, and mitochondrial damage in the liver\(^ {[64]} \). These cascades may cause systemic low-grade inflammation in addition to liver inflammation (Figure 1).

**THERAPEUTIC TARGETS**

**General anti-inflammatories**

The first-line therapy for alcoholic liver disease is alcohol abstinence with nutritional support\(^ {[3,7,65]} \). However, therapeutic lifestyle changes are not easy in clinical practice and may not be sufficient for some patients. Corticosteroids, pentoxifylline, and TNF-α antagonist have been identified as therapeutic agents for severe alcoholic hepatitis. Among them, corticosteroids and pentoxifylline are currently recommended\(^ {[7]} \). Glucocorticoids could reduce immune activation by blocking cytotoxic and inflammatory signal pathways, and pentoxifyllin plays an anti-inflammatory role as a non-selective phosphodiesterase inhibitor and TNF-α suppressor\(^ {[66]} \). Although TNF-α has been regarded as a predictor for the severity of alcoholic hepatitis and TNF-α antagonist reduces liver damage in alcohol-fed animals, clinical trials with TNF-α antibody have not shown consistent results\(^ {[67-69]} \).
TNF-α antibody or corticosteroids may induce a condition that causes patients to be susceptible to infections because of immune suppression\(^2\). Pentoxifylline may be considered in patients with severe alcoholic hepatitis who cannot use corticosteroids\(^3\).

**Antioxidants**

Antioxidants such as N-acetylcysteine have been reported to reduce inflammatory markers and liver fat accumulation in alcohol-fed animals\(^7\). \(\beta\)-adensosylmethionine could increase cellular antioxidant glutathione in patients with alcoholic liver disease\(^7\). Betaine, precursor to \(\beta\)-adensosylmethionine, has also been reported to attenuate alcoholic liver disease\(^7\). In clinical trials, \(\beta\)-adensosylmethionine has shown improved survival in patients with less advanced liver cirrhosis\(^7\) but has not been consistently effective in treating alcoholic liver disease\(^7\). Antioxidants including phytochemicals such as resveratrol and carotenoids are successful for treating alcohol-fed animals, but lack convincing benefits in human patients\(^7\). Oxidative stress may be more pronounced in early stages of alcoholic liver disease, which is found in most animal models, but plays a minor role in later stages of alcoholic liver disease. Actually, administration of antioxidants cocktail has shown inferior survival rates compared to corticosteroid administration in patients with severe alcoholic hepatitis\(^7\).

**Gut microflora and LPS pathway**

The gut-liver interaction has been identified as an important interaction for liver health and prevention of systemic inflammation. In this regard, the modulation of gut microflora and LPS pathway could be used to treat alcoholic liver disease\(^1\) (Figure 2). For the former, probiotics and bioactive extracts may provide therapeutic benefit in patients with alcoholic liver disease\(^1\). In addition, non-absorbable antibiotics such as rifaximin and/or probiotics can modify the gut microflora and help reduce the risk of hepatic encephalopathy\(^1\). For the latter, TLR4 antagonists that modify the LPS pathway have been proposed as therapeutic materials for chronic liver disease\(^2\).

**Other therapeutic considerations**

Several surrogate agents for treating alcoholic liver disease are being investigated. Global suppression of inflammatory responses could lead to undesirable side effects such as immune suppression. Therefore, specific anti-inflammatory targeting may be more promising. Recent studies have shown that IL-22 has hepatoprotective properties including antioxidant, anti-steatotic, and anti-microbial effects\(^1,3\). Moreover, the IL-22 receptor exists only on epithelial cells such as hepatocytes, and side effects that target this receptor may be minimal. Also, IL-8 and IL-17 have been related to neutrophil infiltration, TNF-α augmentation, and autoimmune\(^1\). Therefore, based on the cytokine and immune cell profiles, specific intervention may merit serious consideration to reduce the inflammatory response with minimal side effects.

**CONCLUSION**

Chronic inflammation in alcoholic liver disease and related systemic illness is mediated by a direct response to alcohol and an indirect inflammatory response to gut microflora-derived LPS, leading to a stronger oxidative-inflammatory response. In addition to alcohol abstinence, integrative therapeutic strategies to reduce inflammatory cascades may be needed to treat and prevent alcoholic liver disease.

**REFERENCES**


Zakhar S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 2006; 29: 245-254 [PMID: 17178403 DOI: 10.4049/jahr.29.3.245]


Bishaye A, Davesh AS, Folit T, McGorry R. Resveratrol


P- Reviewers: Buechler C, Saito T, Yang SC
S- Editor: Qi Y
L- Editor: A
E- Editor: Liu XM